Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01476904 · ClinicalTrials.gov registry record · Phase 3
Safety Study in Adolescent and Adult Patients With Asthma
A Phase 3 study, sponsored by Amphastar Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 208
- Enrollment target
NCT01476904 is a Phase 3 study that has completed, run by Amphastar Pharmaceuticals. The registered enrollment target is 208 participants.
The verdict
NCT01476904, a Phase 3 study, has completed, sponsored by Amphastar Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 208 participants
- Enrollment target
Study Summary
E004-C2 is a continuation of E004-C for safety evaluations with additional 3 months to be able to assess the 6-month safety profile for E004 (epinephrine inhalation) versus placebo in a double-blinded manner.
Interventions
- DRUG Placebo
- DRUG Primatene Mist
- DRUG Epinephrine inhalation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 208 participants |
| Start Date | 2011-11 |
| Est. Completion | 2012-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01476904
The ClinicalTrials.gov registry entry for NCT01476904 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 208 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amphastar Pharmaceuticals, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01476904 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01476904 about?
NCT01476904 is a clinical study titled "Safety Study in Adolescent and Adult Patients With Asthma". E004-C2 is a continuation of E004-C for safety evaluations with additional 3 months to be able to assess the 6-month safety profile for E004 (epinephrine inhalation) versus placebo in a double-blinded manner.
What is the current status of trial NCT01476904?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 208 participants. The study started on 2011-11. Estimated completion is 2012-07.
What interventions are being tested in trial NCT01476904?
The interventions under investigation include: Placebo (DRUG), Primatene Mist (DRUG), Epinephrine inhalation (DRUG).
Who is sponsoring clinical trial NCT01476904?
This trial is sponsored by Amphastar Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.